Endocrine Abstracts

Introduction: Adult Growth Hormone Deficient (AGHD) patients have often a difficult path from diagnosis to treatment. A patient advisory panel was conducted to better understand the AGHD patient journey and how this could be supported. This format was chosen to allow for direct patient to patient interactions and discussions and for physicians to learn.Findings: A total of nine patient advisors (three childhood-onset; six adult-onset, age 33–67 year...

Introduction: Patients with acromegaly have often a challenging path from diagnosis to treatment start and to long-term care. Two separate acromegaly patient advisory panels (one in Europe and one in USA) were conducted with the aim to better learn about their experience and how this could be improved. This format was chosen to allow direct patient to patient interactions and to understand possible unmet needs and opportunities within the acromegaly community. An independent m...

IntroductionEvidence suggests that adults with growth hormone deficiency (AGHD) exhibit metabolic abnormalities that are typical of the metabolic syndrome and are risk factors for type 2 diabetes (T2D). Concerns about undesirable effects of growth hormone replacement therapy (GHRT) on glucose metabolism have been raised, but the risk of T2D from AGHD has mixed evidence. This analysis aims to evaluate cardiovascular (CV) and metabolic safety of GHRT in th...

Introduction: There are limited data on the effectiveness and safety of GHRT in older patients with AGHD. We compared real-world GHRT outcomes in older (aged ≥60 years) vs middle-aged (35–<60 years) adults.Methods: NordiNet® IOS (NCT00960128) and ANSWER (NCT01009905) were non-interventional studies investigating long-term effectiveness and safety of GHRT with Norditropin® (somatropin, Novo Nordisk). Safety was assessed in the ful...